Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances

Pharmacological Reports

Volumn 62, Issue 1, 2010, Pages 120-130

  Krysiak, Robert ^a   Stachura Kułach, Aldona ^a   Okopień, Bogułsaw ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Cytokines; Fenofibrate; Impaired fasting glucose; Impaired glucose tolerance; Mixed dyslipidemia; Monocytes

Indexed keywords

FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 77950855915     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70249-8     Document Type: Article

References (29)

1. Anderlová K, Dolezalová R, Housová J, Bosanská L, Haluzíková D, Kremen J, Skrha J, Haluzík M: Influence of PPAR-agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes. Physiol Res, 2007, 56, 579-586.
2. Balakumar P, Rose M, Singh M: PPAR ligands: are they potential agents for cardiovascular disorders? Pharmacology, 2007, 80, 1-10.
3. Ballantyne CM, Nambi V: Markers of inflammation and their clinical significance. Atheroscler Suppl, 2005, 6, 21-29.
4. Bianchi C, Penno G, Romero F, Del Prato S, Miccoli R: Treating the metabolic syndrome. Expert Rev Cardiovasc Ther, 2007, 5, 491-506.
5. Braunersreuther V, Mach F, Steffens S: The specific role of chemokines in atherosclerosis. Thromb Haemost, 2007,97,714-721.
6. Fulop T, Tessier D, Carpentier A: The metabolic syndrome. Pathol Biol, 2006, 54, 375-386.
7. Hansson GK, Robertson AK, Söderberg-Nauclér C: Inflammation and atherosclerosis. Annu Rev Pathol, 2006,1,297-329.
8. Inoue I, Takahashi K, Katayama S, Akabane S, Negishi K, Suzuki M, Ishii J, Kawazu S: Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance. Diabetes Res Clin Pract, 1994, 25, 199-205.
9. Keating GM, Croom KF: Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Drugs, 2007, 67, 121-153.
10. Keating GM, Ormrod D: Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Drugs, 2002, 62, 1909-1944.
11. Krysiak R., Łabuzek K, Okopień B.: Effect of atorvastatin and fenofibric acid on adipokine release from visceral nd subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects. Pharmacol Rep, 2009, 60, 1134-1145.
12. Laaksonen DE, Niskanen L, Lakka HM, Lakka TA, Uusitupa M: Epidemiology and treatment of the metabolic syndrome. Ann Med, 2004, 36, 332-346.
13. Linton MF, Fazio S: Macrophages, inflammation, and atherosclerosis. Int J Obes Relat Metab Disord, 2003, 27, Suppl 3,S35-S40
14. Loppnow H, Westphal E, Buchhorn R, Wessel A, Werdan K: Interleukin-1 and related proteins in cardiovascular disease in adults and children. Shock, 2001, 16, Suppl 1, 3-9.
15. Manninen V, Tenkanen L, Koskinen, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation, 1992, 85, 37-45.
16. Okopień B, Haberka M, Madej A, Belowski D, Łabuzek K, Krysiak R, Zieliński M et al.: Extralipid effects of micronized fenofibrate in dyslipidemic patients. Pharmacol Rep, 2006, 58, 729-735.
17. Okopień B, Kowalski J, Krysiak R, Łabuzek K, Stachura-Kułach A, Kułach A, Zieliński M et al.: Monocyte suppressing action of fenofibrate. Pharmacol Rep, 2005, 57, 367-372.
18. Okopień B, Krysiak R, Haberka M, Herman ZS: Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipidemia. J Cardiovasc Pharmacol, 2005, 45, 314-320.
19. Okopień B, Krysiak R, Herman ZS: Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab, 2006, 91, 1770-1778.
20. Okopień B, Krysiak R, Kowalski J, Madej A, Belowski D, Zieliński M, Herman ZS: Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates. J Cardiovasc Pharmacol, 2005, 46, 377-386.
21. Okopień B, Krysiak R, Kowalski J, Madej J, Belowski D, Zielinski M, Łabuzek K, Herman ZS: The effect of statins and fibrates on interferon- and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis, 2004, 176, 327-335.
22. Petersen JL, McGuire DK: Impaired glucose tolerance and impaired fasting glucose - a review of diagnosis, clinical implications and management. Diab Vasc Dis Res, 2005, 2, 9-15.
23. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high density lipoprotein intervention trial (VA-HIT). Arch Intern Med, 2002, 162, 2597-2604.
24. Shu H, Wong B, Zhou G, Li Y, Berger J, Woods JW, Wright SD,Cai TQ: Activation of PPAR or reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun, 2000, 267, 345-349.
25. Tan CE, Chew LS, Chio LF, Tai ES, Lim HS, Lim SC, Jayakumar L et al.: Cardiovascular risk factors and LDL subfraction profile in Type 2 diabetes mellitus subjects with good glycaemic control. Diabetes Res Clin Pract, 2001,51,107-114.
26. Tedgui A, Mallat Z: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev, 2006, 86, 515-581.
27. Twigg SM, Kamp MC, Davis TM, Neylon EK, Flack JR: Australian Diabetes Society; Australian Diabetes Educators Association: Prediabetes: a position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust, 2007, 186, 461-465.
28. Vega GL, Cater NB, Hadizadeh DR 3rd, Meguro S, Grundy SM: Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. Clin Pharmacol Ther, 2003, 74, 236-244.
29. Wysocki J, Belowski D, Kalina M, Kochanski L, Okopien B, Kalina Z: Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome. Int J Clin Pharmacol Ther, 2004, 42, 212-217.